Shivalik Rasayan
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
May 27 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD MARCH-QUARTER CONSOL NET PROFIT 45.3 MILLION RUPEES
SHIVALIK RASAYAN LTD MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 1.03 BILLION RUPEES
Further company coverage: SIVA.NS
(([email protected];))
May 27 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD MARCH-QUARTER CONSOL NET PROFIT 45.3 MILLION RUPEES
SHIVALIK RASAYAN LTD MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 1.03 BILLION RUPEES
Further company coverage: SIVA.NS
(([email protected];))
Oct 3 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
US FDA APPROVED API FACILITY OF SHIVALIK RASAYAN AT DAHEJ
US FDA RELEASED ESTABLISHMENT INSPECTION REPORT FOR DAHEJ INSPECTION
Source text for Eikon: ID:nBSE6BVxKL
Further company coverage: SIVA.NS
(([email protected];;))
Oct 3 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
US FDA APPROVED API FACILITY OF SHIVALIK RASAYAN AT DAHEJ
US FDA RELEASED ESTABLISHMENT INSPECTION REPORT FOR DAHEJ INSPECTION
Source text for Eikon: ID:nBSE6BVxKL
Further company coverage: SIVA.NS
(([email protected];;))
** Shares of agrochemicals and active pharma ingredients (API) maker Shivalik Rasayan SIVA.NS rise 5% to 590.35 rupees
** Co says U.S. Food and Drug Administration completed inspection at its Dahej factory, Gujarat, with seven procedural observations
** Shares down 20% YTD after falling 2.6% in 2023
(Reporting by Sethuraman NR in Bengaluru)
(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))
** Shares of agrochemicals and active pharma ingredients (API) maker Shivalik Rasayan SIVA.NS rise 5% to 590.35 rupees
** Co says U.S. Food and Drug Administration completed inspection at its Dahej factory, Gujarat, with seven procedural observations
** Shares down 20% YTD after falling 2.6% in 2023
(Reporting by Sethuraman NR in Bengaluru)
(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))
April 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - COMPLETION OF US FDA INSPECTION AT API FACILITY OF SHIVALIK RASAYAN LIMITED AT DAHEJ UNIT
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
Source text for Eikon: ID:nBSE6fcsV1
Further company coverage: SIVA.NS
(([email protected];;))
April 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - COMPLETION OF US FDA INSPECTION AT API FACILITY OF SHIVALIK RASAYAN LIMITED AT DAHEJ UNIT
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY
Source text for Eikon: ID:nBSE6fcsV1
Further company coverage: SIVA.NS
(([email protected];;))
March 26 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
APPROVALS TO CONSTRUCT RG-4 AT DAHEJ UNIT-I ARE RECEIVED FROM GIDC
VENDORS/ CONTRACTORS ARE FINALISED AND CONSTRUCTION ACTIVITIES STARTED
Source text for Eikon: ID:nBSEb4Ll6P
Further company coverage: SIVA.NS
(([email protected];))
March 26 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
APPROVALS TO CONSTRUCT RG-4 AT DAHEJ UNIT-I ARE RECEIVED FROM GIDC
VENDORS/ CONTRACTORS ARE FINALISED AND CONSTRUCTION ACTIVITIES STARTED
Source text for Eikon: ID:nBSEb4Ll6P
Further company coverage: SIVA.NS
(([email protected];))
March 7 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ALL REQUIRED LICENSES TO START MANUFACTURING AT NEWLY BUILD AGRO-CHEMICAL PLANT RECEIVED NOW
TRIAL BATCHES FOR P.G. EASTER, AZOXYSTROBIN, PYMETROZINE HAS BEEN TAKEN SUCCESSFULLY
COMMERCIAL PRODUCTIONS SHALL START FROM APRIL, 2024
Source text for Eikon: ID:nBSE1yXL5
Further company coverage: SIVA.NS
(([email protected];))
March 7 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ALL REQUIRED LICENSES TO START MANUFACTURING AT NEWLY BUILD AGRO-CHEMICAL PLANT RECEIVED NOW
TRIAL BATCHES FOR P.G. EASTER, AZOXYSTROBIN, PYMETROZINE HAS BEEN TAKEN SUCCESSFULLY
COMMERCIAL PRODUCTIONS SHALL START FROM APRIL, 2024
Source text for Eikon: ID:nBSE1yXL5
Further company coverage: SIVA.NS
(([email protected];))
Jan 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RECEIVED CERTIFICATE OF SUITABILITY FOR PIRFENIDONE FROM EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINE & HEALTHCARE
Further company coverage: SIVA.NS
(([email protected];))
Jan 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RECEIVED CERTIFICATE OF SUITABILITY FOR PIRFENIDONE FROM EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINE & HEALTHCARE
Further company coverage: SIVA.NS
(([email protected];))
Aug 8 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RE-APPOINTS DR. VIMAL KUMAR SHRAWAT AS MANAGING DIRECTOR
Source text for Eikon: ID:nNSE1HL4BC
Further company coverage: SIVA.NS
(([email protected];))
Aug 8 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
RE-APPOINTS DR. VIMAL KUMAR SHRAWAT AS MANAGING DIRECTOR
Source text for Eikon: ID:nNSE1HL4BC
Further company coverage: SIVA.NS
(([email protected];))
** Shares of Shivalik Rasayan SIVA.NS rise as much as 5.2% to 787.55 rupees, biggest intraday pct gain since June 16
** Active pharma ingredient (API)-maker says Centre for Drug Evaluation, China, has permitted evaluation of its anti-leukemia API Bendamustine
** Process of evaluation and approval underway - SIVA
** Trading volume at ~11,300 shares, slightly below the 30-day avg of ~12,800 shares as of 12:10 p.m. IST
** Stock last down ~1% YTD
(Reporting by Biplob Kumar Das in Bengaluru)
** Shares of Shivalik Rasayan SIVA.NS rise as much as 5.2% to 787.55 rupees, biggest intraday pct gain since June 16
** Active pharma ingredient (API)-maker says Centre for Drug Evaluation, China, has permitted evaluation of its anti-leukemia API Bendamustine
** Process of evaluation and approval underway - SIVA
** Trading volume at ~11,300 shares, slightly below the 30-day avg of ~12,800 shares as of 12:10 p.m. IST
** Stock last down ~1% YTD
(Reporting by Biplob Kumar Das in Bengaluru)
July 19 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ISSUED LOA TO MEDICAMEN BIOTECH, TO USE DMF GRADE BORTEZOMIB API FOR FORMULATION OF BORTEZOMIB INJECTION 3.5MG/ VIAL
Source text for Eikon: ID:nBSE219bhg
Further company coverage: SIVA.NS
(([email protected];;))
July 19 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
ISSUED LOA TO MEDICAMEN BIOTECH, TO USE DMF GRADE BORTEZOMIB API FOR FORMULATION OF BORTEZOMIB INJECTION 3.5MG/ VIAL
Source text for Eikon: ID:nBSE219bhg
Further company coverage: SIVA.NS
(([email protected];;))
May 30 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - TO CONSIDER PROPOSAL FOR RAISING FUNDS
Source text for Eikon: ID:nBSEDksnd
Further company coverage: SIVA.NS
(([email protected];))
May 30 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:
SHIVALIK RASAYAN LTD - TO CONSIDER PROPOSAL FOR RAISING FUNDS
Source text for Eikon: ID:nBSEDksnd
Further company coverage: SIVA.NS
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Shivalik Rasayan do?
Established in 1981, Shivalik Rasayan Ltd. (SRL) is a leading manufacturer of international quality Malathion Technical and Dimethoate Technical, well established in Indian and foreign markets.
Who are the competitors of Shivalik Rasayan?
Shivalik Rasayan major competitors are Medico Remedies, Medicamen Biotech, Trident Lifeline, Albert David, Lyka Labs, Ambalal Sarabhai Ent, Gennex Laboratories. Market Cap of Shivalik Rasayan is ₹343 Crs. While the median market cap of its peers are ₹311 Crs.
Is Shivalik Rasayan financially stable compared to its competitors?
Shivalik Rasayan seems to be less financially stable compared to its competitors. Altman Z score of Shivalik Rasayan is 2.77 and is ranked 6 out of its 8 competitors.
Does Shivalik Rasayan pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Shivalik Rasayan latest dividend payout ratio is 4.72% and 3yr average dividend payout ratio is 4.78%
How has Shivalik Rasayan allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Shivalik Rasayan balance sheet?
Balance sheet of Shivalik Rasayan is moderately strong.
Is the profitablity of Shivalik Rasayan improving?
Yes, profit is increasing. The profit of Shivalik Rasayan is ₹17.97 Crs for TTM, ₹16.7 Crs for Mar 2025 and ₹12.72 Crs for Mar 2024.
Is the debt of Shivalik Rasayan increasing or decreasing?
Yes, The net debt of Shivalik Rasayan is increasing. Latest net debt of Shivalik Rasayan is ₹79.28 Crs as of Mar-26. This is greater than Mar-25 when it was ₹48.86 Crs.
Is Shivalik Rasayan stock expensive?
Shivalik Rasayan is not expensive. Latest PE of Shivalik Rasayan is 28.25, while 3 year average PE is 55.32. Also latest EV/EBITDA of Shivalik Rasayan is 9.23 while 3yr average is 23.56.
Has the share price of Shivalik Rasayan grown faster than its competition?
Shivalik Rasayan has given lower returns compared to its competitors. Shivalik Rasayan has grown at ~-33.16% over the last 3yrs while peers have grown at a median rate of 2.7%
Is the promoter bullish about Shivalik Rasayan?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Shivalik Rasayan is 47.37% and last quarter promoter holding is 47.37%.
Are mutual funds buying/selling Shivalik Rasayan?
There is Insufficient data to gauge this.